

1 **Dominant negative ADA2 mutations cause ADA2 deficiency in** 2 **heterozygous carriers**

3 Marjon Wouters¹, Lisa Ehlers^{1,2,3,4,5}, Wout Van Eynde⁶, Meltem Ece Kars⁷, Selket Delafontaine^{1,8}, Verena
4 Kienapfel¹, Mariia Dzhush¹, Rik Schrijvers^{9,10}, Petra De Haes^{11,12}, Sofie Struyf¹³, Giorgia Bucciol^{1,8}, Yuval
5 Itan^{6,14,15}, Alexandre Bolze¹⁶, Arnout Voet⁶, Anneleen Hombrouck¹, Leen Moens¹, Benson Ogunjimi¹⁷,
6 ¹⁸ and Isabelle Meyts^{1,8}.

7 ¹Laboratory Inborn errors of Immunity, Department of Microbiology, Immunology and
8 Transplantation, KU Leuven, Leuven, Belgium

9 ² Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charite
10 – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-
11 Universität zu Berlin, Berlin, Germany

12 ³ Berlin Institute of Health at Charite – Universitätsmedizin Berlin, Berlin, Germany

13 ⁴ German Center for Child and Adolescent Health (DZKJ), partner site Berlin, Berlin, Germany

14 ⁵ Deutsches Rheuma-Forschungszentrum, an Institute of the Leibniz Association, Berlin,
15 Germany

16 ⁶ Biochemistry, Molecular and Structural Biology, Department of Chemistry, KU Leuven, Leuven,
17 Belgium

18 ⁷ The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai,
19 New York City, United States of America

20 ⁸ Department of Pediatrics, UZ Leuven, Leuven, Belgium

21 ⁹ Allergy and Clinical Immunology Research Group, Department of Microbiology, Immunology and
22 Transplantation, KU Leuven, Leuven, Belgium

23 ¹⁰ Department of General Internal Medicine, UZ Leuven, Leuven, Belgium

24 ¹¹ Department of Dermatology, UZ Leuven, Leuven, Belgium

25 ¹² Department of Microbiology, Immunology and transplantation, KU Leuven, Leuven, Belgium

26 ¹³ Molecular Immunology (Rega Institute), Department of Microbiology, Immunology and
27 Transplantation, KU Leuven, Belgium

28 ¹⁴ Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New
29 York, NY, 10029, USA

30 ¹⁵ Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New
31 York, NY, 10029, USA

32 ¹⁶ Helix, San Mateo, CA, United States of America

33 ¹⁷ Department of Pediatrics, Antwerp University Hospital, Antwerp, Belgium.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 ¹⁸ Antwerp Center for Translational Immunology and Virology (ACTIV), Center for Health Economics
35 Research and Modeling Infectious Diseases (CHERMID), Vaccine and Infectious Disease Institute,
36 University of Antwerp, Antwerp, Belgium
37
38 @: Isabelle Meyts, Herestraat 49 3000 Leuven, Belgium, +3216343841,Isabelle.Meyts@uzleuven.be
39 Conflict-of-interest statement:


40 LRD KU Leuven receives advisory board honorary from Boehringer-Ingelheim and Takeda for IM.

41 IM is the chair of the CSL Behring Chair in Primary Immunodeficiencies, paid to KU Leuven.

42 Abstract

43 Human ADA2 deficiency (DADA2) is an inborn error of immunity with a broad clinical phenotype which
44 encompasses vasculopathy including livedo racemosa and lacunar strokes, as well as hemato-
45 immunological features. Diagnosis is based on the combination of decreased serum ADA2 activity and
46 the identification of biallelic deleterious alleles in the *ADA2* gene. DADA2 carriers harbor a single
47 pathogenic variant in *ADA2* and are mostly considered healthy and asymptomatic. However, some
48 DADA2 carriers present a phenotype compatible with DADA2. Here, we report ten patients from seven
49 kindreds presenting with a phenotype indicative of DADA2, in whom only a single pathogenic variant
50 (p.G47R, p.G47V, p.R169Q, p.H424N) was identified. To test whether being heterozygote for specific
51 variants could explain the patients' phenotype, we investigated the effect of the *ADA2* missense
52 variants p.G47A, p.G47R, p.G47V, p.G47W, p.R169Q, p.E328K, p.T360A, p.N370K, p.H424N and
53 p.Y453C on *ADA2* protein expression, secretion and enzymatic activity. Functional studies indicate that
54 they exert a dominant negative effect on *ADA2* enzymatic activity, dimerization and/or secretion. At
55 the molecular level, heterozygosity for these variants mimics what is observed in DADA2. We conclude
56 that humans with heterozygous dominant negative missense variants in *ADA2* are at risk of DADA2.

57 Graphical abstract



58

59

60

61 **Main text**

62 **Introduction**

63 Human ADA2 deficiency (DADA2) is an inborn error of immunity (IEI) caused by biallelic deleterious
64 mutations in *ADA2*, characterized by autoinflammation in the form of recurrent fevers and vasculitis
65 ranging from livedo racemosa to lacunar strokes (1, 2). As additional patients have been described, the
66 phenotype has expanded to include pure red cell aplasia, various forms of cytopenias and bone
67 marrow failure. Furthermore, lymphoproliferation, hepatosplenomegaly, immunodeficiency with
68 hypogammaglobulinemia, sinopulmonary and severe viral infections have been added to the
69 phenotype (3, 4). DADA2 patients can also present with hematological malignancy and
70 hemophagocytosis (5). To date, over 150 pathogenic variants in *ADA2* have been described (6). *ADA2*
71 encodes a 59 kD glycoprotein with a signal peptide and a dimerization domain. The theories on disease
72 pathogenesis focus primarily on the reduction or absence of extracellular adenosine deaminase
73 activity due to loss of *ADA2* leading to a skewed macrophage development with predominance of
74 proinflammatory M1 macrophages (7). The cytokine profile of patients is complex, featuring
75 upregulation of both type I as well as type II interferons (IFNs) alongside to other proinflammatory
76 cytokines (8–10). More recently, Greiner-Tollersrud et al. proposed that *ADA2* functions as an
77 adenosine deaminase acting on DNA in the lysosome, where it regulates immune sensing by
78 modulating TLR9 activation (11). Regarding treatment, anti-TNF agents alleviate fever and vasculitis
79 and can prevent strokes in most patients (12). Patients with hematological and immunological
80 manifestations often require hematopoietic stem cell transplantation (13).

81 The diagnosis of DADA2 is based on decreased *ADA2* serum enzyme activity and the identification of
82 two deleterious alleles in the *ADA2* gene (14, 15). A model of genotype / phenotype correlation was
83 proposed, identifying 25% residual adenosine deaminase activity as the pathogenicity threshold when
84 the variant allele was tested in a HEK293T overexpression system (15, 16). In this model, the lowest
85 residual *ADA2* activity in the supernatant is associated with the most severe manifestations of DADA2,
86 including pure red cell aplasia. The variants were tested in a homozygous state (15, 16). This model
87 suggests that pathogenic variants which result in little or no residual activity, could be pathogenic in
88 heterozygous state, especially since *ADA2* functions as a dimer. Interestingly, extended
89 immunophenotyping of carriers of DADA2 (i.e. harboring a single deleterious *ADA2* allele) showed an
90 intermediate phenotype for several of the features identified in DADA2 patients including SIGLEC-1
91 expression (8).

92 Diseased carriers of heterozygous variants have already been described in literature, however without
93 mechanistic validation. In 2022, Moi. et al. reported a 35-year-old woman presenting with common

94 variable immunodeficiency. Childhood medical history revealed large joint arthritis episodes and
95 recurrent infection. Next-generation sequencing identified her as a heterozygous carrier for the R169Q
96 variant in ADA2. She is the mother of a DADA2 patient, homozygous for the R169Q variant (17). Next,
97 a study performed by the French reference center for autoinflammatory diseases investigated the DNA
98 of 66 patients with clinically suspected DADA2. Three patients were found to be carrier of a
99 heterozygous ADA2 variant. In particular, a heterozygous carrier of G47R presented with an
100 inflammatory syndrome characterized by fever and increased CRP levels. Moreover, a papular rash
101 with pruritis and gastrointestinal manifestations were observed (18). In addition, in a Japanese cohort
102 study by Nihira et al. two siblings were reported to suffer from livedo racemosa, renal infarction and
103 neurological manifestations (cerebral infarction and memory disturbance). Next-generation
104 sequencing revealed the presence of a single pathogenic variant E328K (10). Finally, in 2023, Izumo et
105 al. described a 13-year-old girl that was hospitalized with sudden-onset weakness in the right upper
106 and lower limbs caused by a cerebral infarction. Four years earlier, she had presented with livedo. Her
107 treatment included oral anti-platelet drugs and steroid pulse therapy. Additionally, splenic and renal
108 infarction were noted. Measurement of serum ADA2 enzymatic activity revealed levels at 50% of
109 healthy controls. She was diagnosed with polyarteritis nodosa and was treated with prednisone and
110 cyclophosphamide (19). However, she developed a new cerebral infarction and was then started on
111 infliximab. Since then, no reoccurrence of cerebral infarction has been observed. Family history
112 revealed that her father had suffered from an acute subarachnoid hemorrhage in his 40s. Sanger
113 sequencing identified the missense variants F355L and Y453C, without functional validation (19).

114 Our interest in the effect of heterozygous variants was further driven by the finding that in a HEK293T
115 overexpression system, the heterozygous ADA2 condition, expressing 50% R169Q ADA2 and 50% wild-
116 type (WT) ADA2 resulted in reduced total ADA2 protein secretion compared to the homozygous WT
117 ADA2 condition (20). In addition, in clinical practice, we encountered several patients with a
118 phenotype suggestive of DADA2, in whom we identified only a single deleterious allele.

119 In this report, we describe how specific heterozygous variants cause ADA2 deficiency according to the
120 proposed pathogenicity cut-off (16) through distinct dominant negative effects on either ADA2 enzyme
121 activity, dimerization and/or secretion.

122 **Results**

123 **Clinical phenotype and genotype of reported and suspected DADA2 patients in whom only a** 124 **heterozygous variant in ADA2 was identified.**

125 We identified ten patients, from seven kindreds, with a phenotype suggestive of DADA2, each
126 harboring a single mutation in ADA2, in addition to the patients with heterozygous ADA2 variants

127 retrieved from the literature (10, 17–19). Their pedigrees, clinical features and genetic characteristics
128 are summarized in Figure. 1A, Supplemental Tables. 4-6 and Supplemental Figure. 1. All patients were
129 born to non-consanguineous parents of either Moroccan or Belgian descent. Patient 1 (P1) is the son
130 of patient 2 (P2) (kindred A), and patient 3 (P3) is the daughter of patient 4 (P4) (kindred B). For patient
131 5 (P5) (kindred C) and patient 6 (P6) (kindred D) parental DNA was unavailable. Patient 7 (P7) and 8
132 (P8) are the parents of two previously reported DADA2 patients (kindred E), and patient 9 (P9) is the
133 father of two other previously reported DADA2 patients (kindred F). Parental DNA was also unavailable
134 for patient 10 (P10).

135 Five out of ten patients presented with (muco)cutaneous manifestations (Supplemental Table. 4): two
136 with livedo, one with Raynaud phenomenon and two with non-specific cutaneous vasculopathy,
137 including chilblain-like lesions (Supplemental Figure. 1B). Neurological manifestations were observed
138 in three patients: two patients experienced ischemic strokes and brain MRI of P6 revealed white matter
139 lesions. Representative images are shown in Supplemental Figure. 1A and 1C. Immunological and/or
140 hematological manifestations occurred in four patients, including hypogammaglobulinemia in three
141 patients, an insufficient pneumococcal antibody response in two patients, neutropenia and
142 thrombocytopenia in P3 and a deep venous thrombosis with pulmonary embolism in P4. Increased
143 infectious susceptibility to viral and bacterial infections was noted in three patients. Gastro-intestinal
144 manifestations were present in three patients. P3 experienced abdominal pain, chronic dyspepsia,
145 nodular regenerative hyperplasia and portal hypertension, P9 had abdominal pain and P10 presented
146 with hematemesis. Musculoskeletal symptoms were observed in two patients, both of whom had
147 arthritis, with P10 also experiencing tendinitis. Pericarditis was documented in P10. P7 was the only
148 treated with TNF inhibition (TNFi).

149 Whole exome sequencing revealed four distinct heterozygous variants in these patients, the p.H424N
150 variant in P1 and P2, the p.G47V variant in P3-5 and P8, the p.R169Q variant in P6 and P7 and the
151 p.G47R variant in P10. Sanger sequencing of gDNA and cDNA confirmed the pathogenic variants
152 identified via whole exome sequencing. No additional pathogenic variants in *ADA2* were identified.
153 Genetic intolerance scores for *ADA2* support *ADA2*'s role as a recessive gene with limited tolerance for
154 variation, but they do not strongly suggest a dominant pathogenic role in heterozygous mutations
155 (Supplemental Table. 7) (21).

156 To study the potential effect of heterozygous pathogenic variants in *ADA2*, we examined the four
157 variants, resulting in single amino acid substitutions in different domains of the *ADA2* protein,
158 discovered in P1-P10, along with the heterozygous variants reported in the literature (10, 17–19). The
159 variants G47A and G47W were also assessed, as these proven pathogenic variants are located at the

160 same amino acid position as the G47V and G47R found in P3-5, P8 and P10, respectively (Figure. 1B).
161 Proven pathogenic variants T360A and N370K were also included (16).

162 **G47V, R169Q, H424N and Y453C ADA2 variants affect secretion of wild-type ADA2 protein**

163 We assessed the effect of ADA2 missense variants on wild-type (WT) ADA2 protein expression,
164 secretion and enzymatic activity. Therefore, we performed transient transfection of each ADA2 variant
165 alone (homozygous), as well as transient co-transfection of each ADA2 mutant together with WT ADA2
166 to mimic the carrier status (heterozygous) (10, 22). Western blotting of cell lysates on denaturing
167 gels showed that in homozygous condition, ADA2 intracellular protein expression levels of most
168 studied ADA2 variants were comparable to WT100% ADA2, except for G47A, G47R, G47V and Y453C
169 where there was reduction of 20% compared to WT100% (Supplemental Figure. 2A and B,
170 Supplemental Figure. 3A and B, Supplemental Figure. 4A and B). When we assessed ADA2 secretion in
171 homozygous ADA2 variant conditions, no residual ADA2 secretion was observed for the R169Q and
172 Y453C variant (Supplemental Figure. 2A and C). This is in line with the observations by Cheng et al. (23).
173 Compared to WT100%, the secretion of variant H424N was reduced by 80% (Supplemental Figure. 2A
174 and C). A decrease in secretion of around 50% was observed in G47A and G47R when compared to
175 WT100%. The decrease in secretion of variant G47W was more pronounced, with a reduction of 70%.
176 Variant G47V exhibited nearly absent secretion (residual secretion around 10%) (Supplemental Figure.
177 2A and C). Moreover, variants E328K, T360A and N370K showed a reduction of 30%, 20% and 28% in
178 secretion compared to WT100%, respectively (Supplemental Figure. 2A and C, Supplemental Figure.
179 4A and C). Variant F355L exhibited normal protein secretion compared to WT100% (Supplemental
180 Figure. 3A and C).

181 When ADA2 variants were transfected in a heterozygous setup with WT ADA2, we observed a decrease
182 in secretion across all variants except for E328K, F355L, T360A and N370K, when compared to WT50%
183 (Supplemental Figure. 2A and D, Supplemental Figure. 3A and D, Supplemental Figure. 4A and D). While
184 the secretion of ADA2 was only reduced by around 10% for variants G47R, G47V and Y453C, and 20%
185 for G47A and G47W, the reduction below WT50% was more pronounced for R169Q and H424N with a
186 reduction of 70% and 35% respectively (Supplemental Figure. 2A and D). Taken together, our data
187 suggest a dominant negative effect of ADA2 variants R169Q and H424N on WT ADA2 secretion.

188 Since ADA2 dimer formation is required for ADA2 deaminase activity (24), we next assessed the
189 secreted ADA2 dimer formation of each variant in both homozygous and heterozygous conditions in
190 non-denaturing gels. In homozygous setting, F355L shows normal dimer secretion in homozygous
191 conditions (Supplemental Figure. 5A and B). Variant G47A, G47R and G47W show a residual ADA2
192 dimer secretion of around 48%, 53% and 9% respectively compared to WT100% (Figure 2A and B).

193 However, no ADA2 dimers were detected in the supernatant of the homozygous G47V, R169Q, E328K,
194 H424N and Y453C transfection setting (Figure. 2A and B). More interestingly, expression of variants
195 T360A and N370K led mostly to secretion of monomeric ADA2 (Supplemental Figure. 6A and B).

196 In heterozygous setup (WT/M) G47A, G47R, G47W, E328K, T360A and F355L ADA2 variants result in
197 levels of dimer secretion comparable to WT50% (Figure. 2A and C, Supplemental Figure. 4A and C). A
198 small reduction in dimer secretion of 10% was observed in WT/G47V and WT/N370K (Figure. 2A and
199 C, Supplemental Figure. 4A and C). However, R169Q, H424N and Y453C showed a 60%, 50% and 35%
200 decrease respectively in ADA2 dimer secretion when compared to WT50% (Figure. 2A and C). This
201 observation further supports the hypothesis that R169Q, H424N and Y453C exert a dominant negative
202 effect on WT ADA2.

203 **Enzymatic activity of WT ADA2 is affected in a dominant negative manner by G47A, G47R, G47V,**
204 **R169Q, E328K, H424N and Y453C ADA2 variants in overexpression**

205 Next, the ADA2 enzymatic activity of each ADA2 variant was evaluated. We observed normal ADA2
206 enzymatic activity for variant F355L (Supplemental Figure. 7). In the homozygous conditions, a
207 reduction of intracellular ADA2 enzymatic adenosine deaminase activity was observed in all other
208 ADA2 variants studied, when compared to 100% WT ADA2 (Figure. 3A, Supplemental Figure. 8A). For
209 G47A, G47R, G47V and R169Q the residual enzymatic activity was around 25% compared to WT100%.
210 Variant T360A and N370K show a residual enzymatic activity of 35% and 20% respectively. This
211 reduction was even more pronounced in variants G47W, E328K, H424N and Y453C, where the residual
212 enzymatic activity was only 8%, 7%, 11% and 7,5% respectively (Figure. 3A, Supplemental Figure. 8A).
213 When ADA2 activity of secreted homozygously expressed ADA2 variants was examined, G47A,G47R,
214 T360A and N370K showed 25%, 6%, 8% and 7% residual enzymatic activity respectively (Figure. 3B),
215 Supplemental Figure. 8B). However, G47V, G47W, R169Q, E328K, H424N and Y453C exhibited nearly
216 absent enzymatic activity.

217 In heterozygous conditions, variants G47W, T360A and N370K did not affect the enzymatic activity of
218 WT ADA2 (Figure. 3C and D, Supplemental Figure. 8C and D) unlike G47A, G47R, G47V, R169Q, E328K,
219 H424N and Y453C which resulted in enzymatic activity levels below that of the 50% ADA2 WT gene
220 product, suggesting a dominant negative effect. Based on the effect on WT ADA2 enzymatic activity,
221 we made a distinction between absent dominant negative effect (enzymatic activity >75% of WT50%),
222 a weak dominant negative effect (enzymatic activity 50-75% of WT50) and a strong dominant negative
223 effect (enzymatic activity 0-50% of WT50) as described before (16, 25).

224

225 Variants G47A, G47R, G47V and E328K exert a weak dominant negative effect on the enzymatic activity
226 of WT ADA2 both intracellularly as assessed in the whole cell lysate and extracellularly as secreted
227 ADA2 in the supernatant, with a residual enzymatic activity below 75% (Figure. 3C and D). The weak
228 dominant negative effect is most pronounced in the supernatant of variant G47V, with a residual
229 activity of 58% compared to WT50. More interestingly, variant R169Q exhibits a weak dominant
230 negative effect on intracellular ADA2, however it exerts a strong dominant negative effect on the
231 enzymatic activity of secreted WT ADA2 with a residual activity of only 23% (Figure. 3C and D). This is
232 in line with the decrease in dimer secretion observed in the heterozygous R169Q condition.
233 Furthermore, variant H424N has a strong dominant negative effect on both intracellular as well
234 secreted WT ADA2 enzymatic activity (Figure. 3C and D). This suggests that, in addition to hindrance
235 of ADA2 secretion (Figure. 2), there is also an intrinsic inhibition of the WT ADA2 activity. Lastly, variant
236 Y453C exhibits a strong dominant negative effect with a residual activity of only 41% compared to
237 WT50 both intracellularly in the whole cell lysate as well as extracellularly on secreted ADA2 (Figure.
238 3C and D).

239

240 **Prediction model of ADA2 dimer formation in the presence of ADA2 variants**

241 Molecular dynamics (MD) simulations indicate the contributions of amino acid residues to the stability
242 and conformational dynamics of the complex. To investigate these dynamics within the ADA2 complex,
243 three independent 100 ns MD simulations for both the monomeric WT and mutated ADA2 were
244 performed. After completing the simulations, the B-factors for each individual monomer, which serve
245 as a measure of atomic fluctuation within the structure, were calculated. These B-factors were
246 averaged across all monomers and normalized by comparing them to those obtained from the WT
247 simulations, allowing for a relative assessment of the fluctuation.

248

249 All variants except Y453C result in increased fluctuation in their immediate vicinity and thereby
250 demonstrate increased structural instability (Figure. 4A). Notably, the variants at residues G47 and
251 H424 exhibit heightened fluctuation, particularly in regions corresponding to the dimer interface. This
252 increase in fluctuation may explain the observed decrease in deaminase activity when these variants
253 occur as it may prevent correct folding, leading to aggregation or the formation of the dimer interface.
254 The pathogenic variant R169Q also exhibited heightened fluctuation; however, given its distance from
255 the interface, or the active site, this results in disrupted folding/stability. In the WT structure, R169
256 stabilized the fold with a salt bridge with residue D179, hydrogen bonds with residue T129 and
257 aromatic stacking between the guanidinium group of residue R169 and the aromatic ring of residue
258 Y130 (Figure. 4B). All three are disrupted upon mutation. This impairment could be due to the change
259 from a positively charged side chain to an uncharged, shorter side chain, and thus losing interactions

260 with its neighboring residues. Similarly, variant E328K, which is located in the vicinity of the active site
261 will lead to a disruption of a three strong hydrogen bonds with residues N370, G358 and E359, the
262 latter being essential for catalytic activity (24), leading to loss of structural stability as well as catalytic
263 activity (Figure. 4C). The variant Y453C showed a slight decrease in fluctuation in its immediate vicinity
264 (Figure. 4A). However, due to its distance from the active site or dimerization interface, this is not
265 expected to have an effect on either. In the WT structure, Y453 stabilizes the fold with a hydrogen
266 bond with E94, which is lost upon mutation (Figure. 4D). This mutation to a smaller sidechain with loss
267 of interactions is expected to disrupt the folding.

268

269 **Serum ADA2 enzyme activity of diseased heterozygous carriers of pathogenic ADA2 variants is in the** 270 **carrier range**

271 To assess whether the dominant negative effect of the indicated variants could be discriminated from
272 the patients' sera, we measured the ADA2 enzyme activity in the serum of the 10 suspected DADA2
273 patients. All ADA2 enzyme activity levels were in the range of the heterozygous carriers of pathogenic
274 DADA2 variants (Figure. 5A). While the serum ADA2 activity levels of P4, P5 and P7 were in the lower
275 range of DADA2 carriers, we observed that the serum ADA2 activity levels of P1, P2 and P5 were in the
276 higher carrier range (Figure. 5A). Serum ADA2 levels analyzed by Western Blot showed that ADA2
277 secretion correlated with the serum residual ADA2 enzymatic activity (Figure. 5B- D).

278 **Population genetics and correlation with phenotypes**

279 Next, we investigated the frequency of the identified dominant negative ADA2 variants in the general
280 population by looking at the frequency in the overall gnomAD v4.1.0 samples, and by genetic ancestry
281 (Supplemental Table. 8). We found 1,262 alleles for these variants in gnomAD v4. None of the variants
282 were found at the homozygote state implying that about 0.16% of the general population (1,262 out
283 of 807,088 sequenced at this locus) is heterozygote for a dominant negative variant in ADA2. The most
284 common variant was R169Q , which has a prevalence above 1 in 1,000 in the European Finnish and
285 non-Finnish genetic ancestry groups. Of note, both p.G47R missense variants were most common in
286 the Middle Eastern and South Asian ancestry groups with an allele frequency close to 1 in 1,000.

287 Given the relatively high number of individuals in the UK Biobank and from the Finnish population with
288 a R169Q variant, we sought to investigate the clinical impact of these variants in the UK Biobank (26,
289 27) and in Finngen (28). For the UK Biobank, variant-level pheWAS results were available via two
290 different publicly available resources: (i) Genebass (<https://app.genebass.org/>) calculated associations
291 for 4,529 phenotypes across 394,841 individuals, and (ii) AZ pheWAS portal (<https://azphewas.com/>)
292 calculated associations for ~13K binary and ~5K continuous phenotypes across ~500,000 whole-

293 genome sequenced individuals and reported those with a $p < 0.01$. For FinnGen, we utilized the data
294 freeze 12 results (available on November 4, 2024), which include association results for 2,502
295 phenotype endpoints across 500,348 individuals. We focused our analysis of these results to
296 phenotypes known to be relevant to DADA2, and grouped them based on the organs impacted in order
297 to make it easier to compare the results of the three pheWAS analyses, which used different
298 phenotype definitions. For each of the DADA2 phenotypes, we looked whether cases were enriched in
299 R169Q heterozygotes (Table. 1). Several neurological manifestations compatible with DADA2 were
300 more frequent in R169Q heterozygotes, including stroke, sequelae of cerebrovascular disease and
301 headaches. Vascular dementia was also more frequent. We also observed enrichment related to
302 cutaneous vasculopathy such as vasculitis and Raynaud phenomenon, as well as immunological and
303 bone marrow manifestations. Hodgkin lymphoma and myeloid leukemia were also identified during
304 our search which both have been described in DADA2 patients (4, 29–31). We also found DADA2
305 phenotypes that were not enriched, such as viral warts and cytomegaloviral disease (32, 33).

306 To investigate the effect of heterozygous pLOF ADA2 variants in general, we studied the phenotypic
307 associations of collapsed rare pLOF ADA2 variants in the BioMe BioBank
308 (<https://icahn.mssm.edu/research/ipm/programs/biome-biobank/>) and the UK Biobank (34). The
309 PheWAS identified several phenotypic associations of ADA2 pLOFs that align with ADA2 function and
310 clinical presentation of individuals with autosomal recessive DADA2, including diseases of spleen,
311 abnormal results of study function of liver, transient occlusion of retinal artery, abnormal coagulation
312 profile, cranial nerve disorders, paraplegia and diplegia, granulomatous disorders of skin, ulcerative
313 colitis and elevated blood pressure (Supplemental Figure. 9A and B and Supplemental Data File 5 and
314 6). In conclusion, data from population genetics are supportive of a DADA2 disease state in distinct
315 heterozygous carriers.

316 Discussion

317 Here we report a cohort of heterozygous carriers of pathogenic ADA2 variants presenting with DADA2
318 clinical features. In vitro study of the ADA2 variants identified in this patient cohort revealed that
319 R169Q, H424N and Y453C affect secretion of WT ADA2 protein. Moreover, we demonstrate a
320 dominant negative effect on the enzymatic activity of WT ADA2 by variants G47A, G47R, G47V, R169Q,
321 E328K, H424N and Y453C both intracellularly and extracellularly. Using the HEK293T overexpression
322 model, biochemical modeling and population genetics, we provide proof of principle for the
323 observation that heterozygous carriers of ADA2 variants can be diseased. In two of the pedigrees, there
324 is an autosomal dominant (AD) pattern of DADA2, albeit with incomplete penetrance. To highlight that
325 the dominant negative effect is variant-specific, we also functionally evaluated ADA2 variants that have

326 no dominant negative effect and that are only pathogenic in homozygous or compound heterozygous
327 state with another pathogenic variant. For variant G47W, the change of a small amino acid (glycine) to
328 a large hydrophobic amino acid (tryptophan) could prevent correct folding which in turn could affect
329 the protein stability and formation of both homodimers as well as heterodimers with WT ADA2.
330 Variants T360A and N370K appeared to be normally secreted, however when secretion of ADA2 dimers
331 was assessed, mainly monomeric ADA2 was detected. This could explain that when present in a
332 homozygous condition, low residual enzymatic activity is observed, since dimer formation is essential
333 for full adenosine deaminase activity (24).

334 Our study has important clinical implications. First, we provide experimental evidence for the clinical
335 observation of DADA2 disease in heterozygous carriers in the well-established HEK293T
336 overexpression model (16). Based on Jee et al., the carrier frequency of pathogenic ADA2 variants is
337 estimated to be 1 in 236 when 25% residual enzymatic activity in overexpression is used as cut-off to
338 determine deleterious variants (15). The HEK293T cell overexpression model to study the impact of
339 suspected pathogenic variants has shown that variants associated with disease have variable residual
340 enzyme activity in the supernatant (15, 16). However, although several publications mention disease
341 status in heterozygous carriers (10, 17–19), a potential mechanism has not been explored. Our study
342 shows that different variants exert distinct effects on the WT ADA2 glycoprotein in overexpression.
343 Some variants affect WT ADA2 because of their intrinsic defect in enzymatic activity. Presumably they
344 affect WT ADA2 enzymatic activity when they are assembled with WT ADA2 into a dimer complex.
345 Dimer formation of WT ADA2 with ADA2 variants G47A, G47R, G47V and E328K results in weak
346 dominant negative effect on WT ADA2. When ADA2 variant H424N is built in together with WT ADA2
347 to form a dimer, the impact on WT ADA2 is more important resulting in a strong dominant negative
348 effect. Other variants affect WT ADA2 by trapping WT ADA2 intracellularly resulting in decreased
349 secretion of WT ADA2 protein and in this way also affects extracellular ADA2 enzymatic activity in a
350 dominant negative manner, as is the case for ADA2 variant R169Q. Beside the in vitro exploration, we
351 studied population databases. Data from PheWAS show that the heterozygous state for pLOF variants
352 in ADA2 is indeed associated with phenotypes that align with DADA2. When studying the most
353 frequent allele, R169Q, the enriched phenotypes are even more striking, despite the overall low
354 number of cases. Although some phenotypes are soft and subjective like headache, some, like
355 idiopathic thrombopenia and stroke and are more specific and objective. Our data invite therefore to
356 revise the approach to carriers of pathogenic variants for which we describe here a dominant negative
357 effect.

358 Moreover, our findings stress once again the importance of functional validation of ADA2 variants.
359 Izumo et al. describe a patient with typical DADA2 features yet with serum ADA2 enzymatic activity in

360 carrier range. Two missense variants (F355L and Y453C) were identified (19). However, we show that
361 variant F355L exhibits normal ADA2 enzymatic activity and is normally expressed and secreted. Our
362 data suggest that the Y453C variant is the driving pathogenic variant through dominant negative effect.
363 Likewise another report presents a 22-year-old DADA2 patient who harbors two missense variants,
364 E328K and F355L. Based on our findings, F355L is likely not responsible for the phenotype observed in
365 this patient (35).

366 Unfortunately, the disease status of carriers cannot be derived in a straightforward way from serum
367 enzyme activity. Indeed, we observed variable ADA2 enzyme activity in the serum of diseased carriers.
368 However, as remarked by Lee and colleagues, the use of the HEK293T overexpression system allows
369 to increase the dynamic range of the measurements. Moreover, current techniques used to measure
370 ADA2 activity in serum are unable to resolve small differences in activity (16). For that reason, the
371 clinical samples of our patients are not able to reflect the findings from the overexpression system. A
372 future more sensitive assay, or a combination of assays or, if feasible, an omics approach may aid in
373 discriminating diseased carriers from patients. In the same way, we previously published that the
374 phenotype and function of lymphocytes from heterozygous carriers were often intermediate to that
375 of healthy donors and ADA2-deficient patients (8). Carmona-Rivera et al. observed increased low
376 density granulocytes in a heterozygous carrier with adult onset polyarteritis nodosa, when studying
377 the role of neutrophils in DADA2 (36).

378 Interestingly, unlike autosomal recessive (AR) patients harboring homozygous or compound
379 heterozygous pathogenic variants, the patients with heterozygous variants and therefore AD DADA2
380 seem to present DADA2 manifestations later in life. Indeed, except for P1, P3 and P5, all patients
381 presented after the first decade. We can imagine a situation in which the entire genetic make-up but
382 also the exposure to environmental triggers, like infection or vaccination, tip the balance to the onset
383 of clinically overt inflammation. In addition, by inflammaging, heterozygous carriers of dominant
384 negative ADA2 variants may naturally evolve towards a DADA2 phenotype (37). Also, except for two
385 patients with a heterozygous R169Q variant presenting with hypogammaglobulinemia and
386 lymphopenia, no cytopenia was observed and most clinical manifestations consisted of vasculitis. This
387 is in line with the proposition by Lee et al. where the lowest residual ADA2 enzyme activities are linked
388 to bone marrow phenotype and the higher residual ADA2 enzyme activities are linked to vasculitis or
389 vasculopathy (16). Of course, it cannot be excluded that modifier genes are at play or that a second hit
390 in a hitherto undefined gene causes the phenotype in these heterozygous carriers, as is the case in a
391 recent paper by Ahn et al (38). Finally, there remains the possibility that monoallelic expression plays
392 a role, although ADA2 is not listed amongst the genes exhibiting this expression pattern (39, 40). The
393 same hypotheses can be put forward to explain the incomplete penetrance of the phenotype in the

394 heterozygous carriers of the dominant negative variants.

395 Our findings also have important implications for the choice of hematopoietic stem cell donors. Until
396 now, there is debate as to whether procedures with heterozygous carrier donors have worse outcome.
397 However, it can be considered safer to select a matched unrelated donor in cases of siblings carrying
398 monoallelic mutations in ADA2 (13, 41). Our data show that the decision to opt for a matched carrier
399 of a heterozygous variant as donor may depend on the specific variant, highlighting the essence of
400 studying the pathogenicity of a given variant.

401 Our investigations are hampered by our incomplete understanding of the pathophysiology of DADA2.
402 It is still unclear what the physiological function of ADA2 is and whether the intracellular or
403 extracellular fraction is more important. Until now diagnosis of DADA2 has consisted of identification
404 of two known pathogenic variants or variants of uncertain significance combined with the detection
405 of significantly reduced or absent ADA2 activity in the serum or plasma (3, 14). The new data on the
406 lysosomal role of ADA2 further complicate the view on the pathophysiology of this condition and
407 further research is needed to align the prevailing disease models (11). Nevertheless, the finding by
408 Greiner-Tollersrud et al. that the deaminase activity of ADA2 positively correlates with the DNA binding
409 / editing activity stresses the importance of our findings (11).

410 Our data also imply that the incidence of AD and AR ADA2 deficiency is higher than the published 1 in
411 222,164 individuals (15). Indeed, the variants we describe as having a dominant negative effect
412 represent a significant fraction of pathogenic variants. Based on a narrative review by Dzhus et al. in
413 which 495 DADA2 patients reported in literature were included, we calculated the frequency of each
414 variant in the DADA2 patient population (42). Variant G47R (found in P10 of our cohort) is the most
415 common, present in 27% of the patients. R169Q was found in 17% of the patients. G47A, G47V, G47W,
416 E328K and Y453C were more rare, only present in 2%, 3%, 1%, 0,6% and 6% respectively (42). As such,
417 the findings of our work are relevant for an important proportion of DADA2 patients' kindreds. For
418 optimal family counseling, an effort will need to be undertaken to test all variants in heterozygous
419 setting to establish whether they can act in a dominant negative mechanism and cause AD inheritance.

420 Finally, the question is whether heterozygous patients harboring a single pathogenic ADA2 variant with
421 a proven dominant negative effect should receive treatment as for AR DADA2. Given the high
422 proportion of patients (three out of ten in our cohort and three out of seven previously reported in
423 literature) with CNS vascular events as well as renal / splenic infarction (one out of seven previously
424 reported in literature), our findings invite for a reconsideration of treating carriers of dominant
425 negative ADA2 variants with TNFi, as per current guidelines for AR ADA2.

426

427 **Materials and Methods**

428 **Patient selection and variant inclusion**

429 This study was approved by the Ethics Committee for Research of Leuven University Hospitals (project
430 numbers: S51577, S63077). Patients were selected based either on clinical phenotype fitting DADA2.
431 In other cases, symptomatic parents of DADA2 patients were included. In addition, we studied the
432 variants in previously reported patients with a DADA2 phenotype, harboring each a single deleterious
433 variant (10, 17–19). G47A, G47W, T360A and N370K, proven pathogenic variants in homozygous
434 setting, were also included (16).

435 **ADA2 sequencing**

436 Whole exome sequencing (WES) was performed in all patients (Genomics Core Leuven, KU Leuven,
437 Belgium). ADA2 mutations were identified by targeted Sanger sequencing on genomic DNA (in P1-3,
438 P5, P6, P8 and P9) and copy DNA (in P1-3, P5-8) (LGC Genomics). Additional non-pathogenic SNPs
439 observed in ADA2 are presented in Supplemental Table. 1. Primers of targeted Sanger sequencing are
440 available upon request.

441 **Plasmid construction**

442 ADA2 variant constructs were generated by Q5 site-directed mutagenesis (SDM; New England Biolabs)
443 with human wild-type (WT) ADA2 pCMV6 myc-DKK-tagged plasmid (ADA2 transcript 3,
444 NM_001282225 Origene, Cat# RC238645) as backbone. SDM primer sequences designed with
445 NEBaseChanger are provided in Supplemental Table. 2. Plasmids were amplified in heat shock
446 transformed *E.coli* and purification was performed with QIAprep spin Miniprep kit (QIAGEN) according
447 to manufacturer's instructions. Presence of the introduced variants in the plasmids were verified by
448 Sanger sequencing (LGC Genomics).

449 **Cell culture and transfection**

450 Human embryonic kidney (HEK) 293T cells were seeded at $2,5 \times 10^5$ cells/6-well in 2ml 24h prior to
451 transfection. Cells were transfected with 25ng of WT and 25ng of mutant ADA2 plasmids for carrier
452 conditions or 50ng with WT or mutant ADA2 plasmids for homozygous conditions, respectively, using
453 Lipofectamine 2000 Transfection Reagent (ThermoFisher Scientific) according to manufacturer's
454 instruction. Medium was changed 24h after transfection. After 48h, cells and supernatant were
455 collected.

456 **Western Blotting with Denaturing gel**

457 Transfected cells were collected after 48h and whole cell lysate was obtained by lysing cells in 100µl
458 NP-40 buffer (150 mM NaCl, 50 mM Tris-HCl, 1% NP-40, pH 7.4) supplemented with protease inhibitor
459 (Thermo Fisher Scientific). Equivalent amounts of protein were supplemented with 4x Bolt LDS sample
460 buffer (Thermo Fisher Scientific) and 1x Bolt sample reducing agent (Thermo Fisher Scientific).
461 Supernatant from transfected HEK293T cells were diluted 1:7 in 2x Bolt LDS sample buffer and 1x Bolt
462 sample reducing agent (Thermo Fisher Scientific). Equivalent amounts of serum were diluted in in 2x
463 Bolt LDS sample buffer and 1x Bolt sample reducing agent (Thermo Fisher Scientific) Supplemented
464 lysates and supernatant were denatured at 70°C for 5min prior to separation on a 4-12% Bis-Tris
465 acrylamide gel. SeeBlue™ Plus2 Pre-stained Protein Standard (Thermo Fisher Scientific) was used as
466 protein molecular weight marker. Proteins were transferred on a PVDF membrane (Thermo Fisher
467 Scientific) and blocked with 5% bovine serum albumin (BSA) in Tris Saline. Membranes were
468 subsequently probed with ADA2 primary antibody (Abcam, ab288296, 1/1000) overnight at 4°C.
469 Membranes were washed and incubated with HRP-conjugated secondary goat anti-rabbit (Abcam,
470 ab205718, 1/5000) for 1h at room temperature. Anti B-actin antibody (Sigma, A5441, 1/9000) was
471 used as loading control. Pierce ECL western blotting substrate (Thermo Fisher Scientific) and
472 SuperSignal West Pico PLUS Chemiluminescent substrate (Thermo Fisher Scientific) were used to
473 visualize HRP activity. Chemiluminescent signals were detected with a ChemiDoc XRS + Imaging system
474 (Bio-rad) and Image lab 6.0.1 Software was used for densitometric quantification.

475 **Western Blotting with Native gel**

476 Intracellular dimer formation and dimer secretion were analysed on NativePAGE™ 4 to 16%, Bis-Tris
477 (Thermo Fisher Scientific). Equivalent amounts of protein were supplemented with 5% NativePAGE G-
478 250 Sample additive (Thermo Fisher Scientific), 4x NativePAGE sample buffer (Thermo Fisher
479 Scientific), and 1x NativePAGE sample buffer (Thermo Fisher Scientific). Supernatant was diluted 1:4
480 in 5% NativePAGE G-250 Sample additive (Thermo Fisher Scientific), 4x NativePAGE sample buffer
481 (Thermo Fisher Scientific), and 1x NativePAGE sample buffer (Thermo Fisher Scientific). Gel
482 electrophoresis was performed in accordance to manufacturer's instructions. NativeMark™ Unstained
483 Protein Standard (Thermofisher Scientific) was used as protein molecular weight marker. Proteins
484 were transferred on a PVDF membrane (Thermo Fisher Scientific) in the presence of NuPAGE transfer
485 buffer supplemented with 10% methanol. Protein standard (Thermofisher Scientific) was visualized
486 using ponceau S solution (Abcam). Blocking and antibody probing was performed as described
487 previously.

488 **Molecular modeling**

489 The crystal structure and mutated structures of the human ADA2 dimer were prepared using 3D
490 protonation and energy minimization with MOE v.2022.2 (*Molecular Operating Environment (MOE)*,
491 2024.0601 Chemical Computing Group ULC, 910-1010 Sherbrooke St. W., Montreal, QC H3A 2R7,
492 2024.); however, only the monomeric form was retained for simulations. Prior to performing triple
493 molecular dynamics (MD) simulations with GROMACS v.2022.3 (43), the CHARMM-GUI webserver (44,
494 45) was utilized to set up the system, incorporating the 4-point rigid water model (OPC)(46), the ff19SB
495 force field for the protein (47), and the 12–6–4 Lennard-Jones potential model for divalent ions (48).
496 Hydrogen mass repartitioning was applied to the complex to enhance simulation stability without
497 affecting the kinetics of the trajectory or conformational sampling (49, 50).

498 The complexes were placed at the center of a cubic simulation box with a minimum distance of 1 nm
499 from the box boundaries. The system was then solvated with water and neutralized with Cl⁻ and Na⁺
500 counter ions, followed by energy minimization using the steepest descent method (51). Interactions
501 were calculated using the Verlet cutoff scheme (52) and the Particle Mesh Ewald (PME) coulomb type
502 (53). The LINCS algorithm was employed to constrain bond lengths (54).

503 Subsequent to energy minimization, the system was equilibrated to 300 K and 1000 kg/m³ using a 100
504 ps V-rescale thermostat under an NVT ensemble, followed by a 100 ps equilibration under an NPT
505 ensemble with a V-rescale thermostat and C-rescale barostat (55, 56) . Positional restraints were
506 applied to the complex during equilibration. The Parrinello-Rahman barostat (57) was utilized for
507 pressure control during the production run.

508 Figures were made using PyMOL (The PyMOL Molecular Graphics System, Version 3.0 Schrödinger,
509 LLC.).

510 **Population genetics**

511 For variant p.R169Q, we looked at the three variant-based phenome wide association studies
512 (pheWAS) results as calculated and reported in GeneBass (<https://app.genebass.org/>) (26), AZ PheWAS
513 <https://azphewas.com/>) (27) and in FinnGen data freeze 12
514 (https://www.finnngen.fi/en/access_results) (28). Genebass is a resource of exome-based association
515 statistics, made available to the public. The dataset encompasses 4,529 phenotypes with gene-based
516 and single-variant testing across 394,841 individuals with exome sequence data from the UK Biobank
517 (26). AZ PheWAS makes use of the UK Biobank 500k WGS (v2) Public (27). We used the subset of the
518 ~500,000 whole genome sequenced participants released by the UK Biobank that are high quality and
519 predominantly unrelated to evaluate the association between protein-coding variants with ~13K
520 binary and ~5K continuous phenotypes using variant-level and gene-level phenome-wide association
521 studies in 6 ancestry groups (European, Askenazi Jewish, Admixed American, African, East Asian, South

522 Asian). A small number of potentially sensitive phenotypes have been excluded. This portal contains
523 the subset of variant-level associations for which $p \leq 0.01$ and the subset of gene-level associations for
524 which $p \leq 0.1$. Only variants identified in at least 20 samples were included in the variant-level analysis.
525 Please note that no LD pruning has been performed on these associations. The full pheWAS results for
526 p.R169Q are present in Supplemental Data File 1, 2 and 3.

527 The BioMe BioBank comprises exome sequencing data and electronic health records from 30,813
528 genetically diverse participants recruited through Mount Sinai Hospital's primary care clinics. For the
529 UK Biobank analysis, we utilized 200K exome sequences from participants of European ancestry and
530 their electronic health records. Given the low allele frequency of pathogenic ADA2 variants in the
531 population, we collapsed all heterozygous ADA2 variants predicted to have a loss-of-function effect
532 (pLOF) as determined by LoGoFunc (58) and LOFTEE (59) and performed two gene-based phenome
533 PheWAS in the BioMe BioBank and the UK Biobank (Supplemental Data File 4). We used Firth's logistic
534 regression for binary phenotypes obtained from ICD-10 codes matching ADA2 phenotypes
535 (Supplemental Table. 3) and mapped to phecodeX (60) and linear regression for quantitative
536 phenotypes that were curated from laboratory measurements and vital signs. All analyses were
537 adjusted for, age, sex and first ten genetic principal components as covariates.

538 **ADA2 enzyme assay**

539 Adenosine deaminase 2 activity was determined in whole cell lysates and supernatant from HEK293T
540 cells overexpressing ADA2 as well as in human serum. Adenosine deaminase activity was measured in
541 a colorimetric assay adapted from Giusti and Galanti (61). To inhibit ADA1 activity, Erythro-9-(2-
542 hydroxy-3-nonyl) adenine (EHNA) was used. Triplicate measurements were performed for all samples.
543 Enzymatic activity of ADA2 variants overexpressed HEK293T cells was normalized to the activity of WT
544 ADA2.

545 **Statistical analysis**

546 Quantification of Western blotting and ADA2 enzyme assay data were presented as mean \pm standard
547 deviation (SD). Differences between controls and patient populations were statistically assessed using
548 the Mann-Whitney U test. P-values less than 0.05 were considered statistically significant.

549 **Data availability**

550 Source data are provided in the Supporting Data values file. Additional data can be obtained upon
551 request to the corresponding author.

552 **Author contributions**

553 IM, LM, AH, and MW. conceptualized and designed this work. IM, LM, BO, AH, AV, AB, YI, MD, VK, SD,
554 MEK, WVE, LE and MW performed the experiments and carried out data acquisition. BO, GB, PDH and
555 RS provided patient samples. IM, LM, AB, SD, MEK, WVE and MW wrote the manuscript. All authors
556 edited the paper.

557 **Acknowledgments**

558 IM is a Senior Clinical Investigator at the Research Foundation FWO – Flanders, and is supported by
559 the CSL Behring Chair of Primary Immunodeficiencies through KU Leuven, by the FWO Grants
560 G0C8517N, G0B5120N and G0E8420N and by the Jeffrey Modell Foundation. This project has received
561 funding from the European Research Council (ERC) under the European Union’s Horizon 2020 research
562 and innovation programme (grant agreement No. 948959). This work is supported by ERN-RITA. LE was
563 supported by a PhD Fellowship from the Research Foundation FWO – Flanders (grant 11E0123N). LE is
564 a fellow of the BIH Charité Junior Clinician Scientist Program funded by the Charité –
565 Universitätsmedizin Berlin, and the Berlin Institute of Health at Charité (BIH). MEK and YI were funded
566 by the Charles Bronfman Institute for Personalized Medicine at Icahn School of Medicine, Mount Sinai.
567 This work was supported in part through the computational and data resources and staff expertise
568 provided by Scientific Computing and Data at the Icahn School of Medicine at Mount Sinai and
569 supported by the Clinical and Translational Science Awards (CTSA) grant UL1TR004419 from the
570 National Center for Advancing Translational Sciences. This research was conducted using the UK
571 Biobank resource under application number 53074. WVE acknowledges funding of FWO Grant
572 G095522N was used for this research. RS is supported by an FWO senior clinical investigator fellowship
573 (1805523N).

574 **References**

- 575 1. Zhou Q, et al. Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2. *New England*
576 *Journal of Medicine*. 2014;370(10):911–920.
- 577 2. Navon Elkan P, et al. Mutant Adenosine Deaminase 2 in a Polyarteritis Nodosa Vasculopathy. *New*
578 *England Journal of Medicine*. 2014;370(10):921–931.
- 579 3. Wouters M, et al. Human ADA2 Deficiency: Ten Years Later. *Curr Allergy Asthma Rep*. 2024;
580 24(9):477-484.
- 581 4. Gardner LS, et al. Development of EBV Related Diffuse Large B-cell Lymphoma in Deficiency of
582 Adenosine Deaminase 2 with Uncontrolled EBV Infection. *J Clin Immunol*. 2024;44(5) :118.
- 583 5. Lee PY, et al. Evaluation and Management of Deficiency of Adenosine Deaminase 2: An International
584 Consensus Statement. *JAMA Netw Open*. 2023;6(5):e2315894.

- 585 6. Van Gijn ME, et al. New workflow for classification of genetic variants' pathogenicity applied to
586 hereditary recurrent fevers by the International Study Group for Systemic Autoinflammatory Diseases
587 (INSAID). *J Med Genet*. 2018;55(8):530–537.
- 588 7. Zavialov A V., et al. Human adenosine deaminase 2 induces differentiation of monocytes into
589 macrophages and stimulates proliferation of T helper cells and macrophages. *J Leukoc Biol*.
590 2010;88(2):279–290.
- 591 8. Yap JY, et al. Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and
592 Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2
593 Deficiency. *J Clin Immunol*. 2021;41(8):1915–1935.
- 594 9. Belot A, et al. Mutations in CECR1 associated with a neutrophil signature in peripheral blood.
595 *Pediatric Rheumatology*. 2014;12(1). <https://doi.org/10.1186/1546-0096-12-44>.
- 596 10. Nihira H, et al. Detailed analysis of Japanese patients with adenosine deaminase 2 deficiency
597 reveals characteristic elevation of type II interferon signature and STAT1 hyperactivation. *Journal of*
598 *Allergy and Clinical Immunology*. 2021;148(2):550–562.
- 599 11. Greiner-Tollersrud OK, et al. ADA2 is a lysosomal deoxyadenosine deaminase acting on DNA
600 involved in regulating TLR9-mediated immune sensing of DNA. *Cell Rep*. 2024;43(11):114899.
- 601 12. Deutch NT, et al. TNF inhibition in vasculitis management in adenosine deaminase 2 deficiency
602 (DADA2). *Journal of Allergy and Clinical Immunology*. 2022;149(5):1812-1816.e6.
- 603 13. Hashem H, et al. Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency:
604 Report on 30 Patients. *J Clin Immunol*. 2021;41(7):1633–1647.
- 605 14. Meyts I, Aksentijevich I. Deficiency of adenosine deaminase 2 (DADA2): Updates on the phenotype,
606 genetics, pathogenesis, and treatment [preprint]. *J Clin Immunol*. 2018;38(5):569–578.
- 607 15. Jee H, et al. Comprehensive analysis of ADA2 genetic variants and estimation of carrier frequency
608 driven by a function-based approach. *Journal of Allergy and Clinical Immunology*. 2022;149(1):379–
609 387.
- 610 16. Lee PY, et al. Genotype and functional correlates of disease phenotype in deficiency of adenosine
611 deaminase 2 (DADA2). *Journal of Allergy and Clinical Immunology*. 2020;145(6):1664-1672.e10.
- 612 17. Moi L, et al. Common Variable Immunodeficiency in a Carrier of the ADA2 R169Q Variant:
613 Coincidence or Causality?. *J Clin Immunol*. 2022;42(5):959–961.
- 614 18. Rama M, et al. A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2
615 (DADA2): A French reference centres experience. *European Journal of Human Genetics*.
616 2018;26(7):960–971.
- 617 19. Izumo H, et al. A Successful Infliximab Treatment of a Pediatric Case of Severe Polyarteritis Nodosa
618 With a Cerebral Infarction and a Decreased Adenosine Deaminase 2 Activity. *Cureus*.
619 2023;15(10):e47952.
- 620 20. Ehlers L, et al. Human ADA2 deficiency is characterized by the absence of an intracellular
621 hypoglycosylated form of adenosine deaminase 2 [preprint].
622 <https://doi.org/10.1101/2023.10.25.564037>. Posted on bioRxiv October 8, 2024.

- 623 21. Rapaport F, et al. Negative selection on human genes underlying inborn errors depends on disease
624 outcome and both the mode and mechanism of inheritance. *Proceedings of the National Academy of*
625 *Sciences*. 2021;118(3):e2001248118.
- 626 22. Boutboul D, et al. Dominant-negative IKZF1 mutations cause a T, B, and myeloid cell combined
627 immunodeficiency. *Journal of Clinical Investigation*. 2018;128(7):3071–3087.
- 628 23. Chen L, et al. Comparison of disease phenotypes and mechanistic insight on causal variants in
629 patients with DADA2. *Journal of Allergy and Clinical Immunology*. 2023;152(3):771–782.
- 630 24. Zavialov A V., et al. Structural basis for the growth factor activity of human adenosine deaminase
631 ADA2. *Journal of Biological Chemistry*. 2010;285(16):12367–12377.
- 632 25. Asano T, et al. Human STAT3 variants underlie autosomal dominant hyper-IgE syndrome by
633 negative dominance. *Journal of Experimental Medicine*. 2021;218(8):e20202592.
- 634 26. Karczewski KJ, et al. Systematic single-variant and gene-based association testing of thousands of
635 phenotypes in 394,841 UK Biobank exomes. *Cell Genomics*. 2022;2(9):100168.
- 636 27. Sun BB, et al. Plasma proteomic associations with genetics and health in the UK Biobank. *Nature*.
637 2023;622(7982):329–338.
- 638 28. Kurki MI, et al. FinnGen provides genetic insights from a well-phenotyped isolated population.
639 *Nature*. 2023;613(7944):508–518.
- 640 29. Alabbas F, et al. Childhood Hodgkin Lymphoma: Think DADA2. *J Clin Immunol*. 2019;39(1):26–29.
- 641 30. Manhal A, et al. Deficiency of adenosine deaminase 2 leading to recurrent Hodgkin lymphoma: A
642 case report. *SAGE Open Med Case Rep*. 2024;12. <https://doi.org/10.1177/2050313X241260148>.
- 643 31. Van Montfrans JM, et al. Phenotypic variability in patients with ADA2 deficiency due to identical
644 homozygous R169Q mutations. *Rheumatology (United Kingdom)*. 2016;55(5):902–910.
- 645 32. Arts K, et al. Warts and DADA2: a Mere Coincidence?. *J Clin Immunol*. 2018;38(8):836–843.
- 646 33. Drago E, et al. Case Report: Susceptibility to viral infections and secondary hemophagocytic
647 lymphohistiocytosis responsive to intravenous immunoglobulin as primary manifestations of
648 adenosine deaminase 2 deficiency. *Front Immunol*. 2022;13:937108.
649 <https://doi.org/10.3389/fimmu.2022.937108>.
- 650 34. Bycroft C, et al. The UK Biobank resource with deep phenotyping and genomic data. *Nature*.
651 2018;562(7726):203–209.
- 652 35. Keer N, et al. Novel compound heterozygous variants in CECR1 gene associated with childhood
653 onset polyarteritis nodosa and deficiency of ADA2. *Rheumatology*. 2016;55(6):1145–1147.
- 654 36. Carmona-Rivera C, et al. Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis
655 and TNF production in patients with DADA2. *Blood*. 2019;134(4):395–406.
- 656 37. Franceschi C, et al. Inflammaging: a new immune–metabolic viewpoint for age-related diseases.
657 *Nat Rev Endocrinol*. 2018;14(10):576–590.
- 658 38. Ahn TS, et al. Whole Exome Sequencing Reveals Pathogenic Variants in ADA2 and FAS Causing
659 DADA2 and ALPS. *J Clin Immunol*. 2023;43(6):1147–1151.

- 660 39. Akalu YT, Bogunovic D. Inborn errors of immunity: an expanding universe of disease and genetic
661 architecture [preprint]. *Nat Rev Genet*. 2024;25(3):184–195.
- 662 40. Reinius B, Sandberg R. Random monoallelic expression of autosomal genes: Stochastic
663 transcription and allele-level regulation [preprint]. *Nat Rev Genet*. 2015;16(11):653–664.
- 664 41. Hashem H, et al. Hematopoietic stem cell transplantation rescues the hematological,
665 immunological, and vascular phenotype in DADA2. *Blood*. 2017;130(24):2682–2688.
- 666 42. Dzhus M, et al. A Narrative Review of the Neurological Manifestations of Human Adenosine
667 Deaminase 2 Deficiency. *J Clin Immunol*. 2023;43(8):1916–1926.
- 668 43. Van Der Spoel D, et al. GROMACS: Fast, flexible, and free [preprint]. *J Comput Chem*.
669 2005;26(16):1701–1718.
- 670 44. Lee J, et al. CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and
671 CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field. *J Chem Theory Comput*.
672 2016;12(1):405–413.
- 673 45. Jo S, et al. CHARMM-GUI: A web-based graphical user interface for CHARMM. *J Comput Chem*.
674 2008;29(11):1859–1865.
- 675 46. Izadi S, Anandakrishnan R, Onufriev A V. Building water models: A different approach. *Journal of*
676 *Physical Chemistry Letters*. 2014;5(21):3863–3871.
- 677 47. Tian C, et al. Ff19SB: Amino-Acid-Specific Protein Backbone Parameters Trained against Quantum
678 Mechanics Energy Surfaces in Solution. *J Chem Theory Comput*. 2020;16(1):528–552.
- 679 48. Li Z, et al. Systematic Parametrization of Divalent Metal Ions for the OPC3, OPC, TIP3P-FB, and
680 TIP4P-FB Water Models. *J Chem Theory Comput*. 2020;16(7):4429–4442.
- 681 49. Feenstra KA, Hess B, Berendsen HJC. Improving efficiency of large time-scale molecular dynamics
682 simulations of hydrogen-rich systems. *J Comput Chem*. 1999;20(8):786–798.
- 683 50. Hopkins CW, et al. Long-time-step molecular dynamics through hydrogen mass repartitioning. *J*
684 *Chem Theory Comput*. 2015;11(4):1864–1874.
- 685 51. Araya R. Enriching elementary school mathematical learning with the steepest descent algorithm.
686 *Mathematics*. 2021;9(11). <https://doi.org/10.3390/math9111197>.
- 687 52. Páll S, Hess B. A flexible algorithm for calculating pair interactions on SIMD architectures. *Comput*
688 *Phys Commun*. 2013;184(12):2641–2650.
- 689 53. Darden T, York D, Pedersen L. Particle mesh Ewald: An N·log(N) method for Ewald sums in large
690 systems. *J Chem Phys*. 1993;98(12):10089–10092.
- 691 54. Hess B. P-LINCS: A parallel linear constraint solver for molecular simulation. *J Chem Theory Comput*.
692 2008;4(1):116–122.
- 693 55. Bussi G, Donadio D, Parrinello M. Canonical sampling through velocity rescaling. *Journal of*
694 *Chemical Physics*. 2007;126(1). <https://doi.org/10.1063/1.2408420>.
- 695 56. Bernetti M, Bussi G. Pressure control using stochastic cell rescaling. *Journal of Chemical Physics*.
696 2020;153(11). <https://doi.org/10.1063/5.0020514>.

697 57. Parrinello M, Rahman A. Polymorphic transitions in single crystals: A new molecular dynamics
698 method. *J Appl Phys*. 1981;52(12):7182–7190.

699 58. Stein D, et al. Genome-wide prediction of pathogenic gain- and loss-of-function variants from
700 ensemble learning of a diverse feature set. *Genome Med*. 2023;15(1). [https://doi.org/10.1186/s13073-](https://doi.org/10.1186/s13073-023-01261-9)
701 023-01261-9.

702 59. Karczewski KJ, et al. The mutational constraint spectrum quantified from variation in 141,456
703 humans. *Nature*. 2020;581(7809):434–443.

704 60. Shuey MM, et al. Next-generation phenotyping: introducing phecodeX for enhanced discovery
705 research in medical phenomics. *Bioinformatics*. 2023;39(11).
706 <https://doi.org/10.1093/bioinformatics/btad655>.

707 61. Giusti G. Adenosine Deaminase. In: Bergmeyer HU, ed. *Methods of Enzymatic Analysis (Second*
708 *Edition)*. Academic Press; 1974:1092–1099.

709

710

711

712

713

714

715

716

717

718

719


720

721

722

723

724 **Figures**



725

726 **Figure 1. Pedigree analysis of 10 DADA2 carriers presenting with DADA2 clinical phenotype. A.**

727 Pedigrees of seven kindreds showing familial segregation of ADA2 missense variants. M represents

728 mutant. Individuals with unknown genotype are labeled '?'. Black filled symbols represent individuals


729 with 2 pathogenic alleles, half-filled symbols represent individuals with 1 pathogenic allele 'P'

730 represents individuals carrying 1 pathogenic allele with a DADA2 phenotype. **B.** Schematic

731 representation of the functional domains of the ADA2 protein and the location of the ADA2 variants

732 identified in our cohort (labeled '*'), in previous studies (labeled '~') and in literature (labeled '\$').

733




734

735 Figure. 2 Secretion of ADA2 dimers in homozygous or heterozygous state on non-denaturing gel.

736 **A.** ADA2 dimer secretion of HEK293T cells transfected with WT and/or ADA2 variants. Cells and
 737 supernatant were collected 48h after transfection. **B.** Quantification of ADA2 secretion in Supernatant
 738 of transfected HEK293T cells with wild-type ADA2 or ADA2 variants in homozygous conditions. Bar
 739 graphs represent percentage of ADA2 protein secretion relative to wild-type ADA2 100%. **C.**
 740 Quantification of ADA2 secretion of co-transfected HEK293T cells of ADA2 variants together with wild-
 741 type ADA2 in heterozygous conditions. Bar graphs represent percentage of ADA2 secretion relative to
 742 wild-type ADA2 50%. experiments. **A-C.** Image shown represents 3 independent experiments.


743




744
 745 **Figure 3. Adenosine deaminase activity of ADA2 variants in homozygous or heterozygous state A.**
 746 Adenosine deaminase activity in whole cell lysate of HEK293T transfected cells with WT and ADA2
 747 variants in homozygous conditions. Bar graphs represent the percentage of enzymatic activity relative
 748 to wild-type ADA2 100%. **B.** Adenosine deaminase activity in supernatant of HEK293T transfected cells
 749 with WT and ADA2 variants in homozygous conditions. Bar graphs represent the percentage of
 750 enzymatic activity relative to wild-type ADA2 100%. **C.** Adenosine deaminase activity whole cell lysate
 751 of HEK293T transfected cells with WT and/or ADA2 variants in heterozygous conditions. Bar graphs
 752 represent the percentage of enzymatic activity relative to wild-type ADA2 50%.. **D.** Adenosine
 753 deaminase activity in supernatant of HEK293T transfected cells with WT and/or ADA2 variants. Bar
 754 graphs represent the percentage of enzymatic activity relative to wild-type ADA2 50%.. **A-D.** Data
 755 represents mean \pm SD from 3 independent experiments.

A


G47




R169Q





E328K



H424N




Y453C




757


B



C



D



758


759 Figure 4. Molecular modeling of ADA2 variants G47A, G47R, G47V, G47W, R169Q, E328K, H424N and
760 Y453C.

761 **A.** Comparative plots of the different mutations which displays the variability of B-factor values along
762 the protein backbone compared to the wild target. Blue backbones represent lower fluctuations
763 compared to the wild target, red backbones represent higher fluctuations. **B.** Zoom-in of residue
764 R169 in the wild target protein. R169 is shown in magenta. Polar and aromatic interactions are shown
765 as dashed lines. **C.** Zoom-in of residue E328 in the wild target protein. E328 is shown in magenta. Polar

766 interactions are shown as dashed lines. **D.** Zoom-in of residue Y453 in the wild target protein. Y453
767 is shown in magenta. Polar interactions are shown as dashed lines.

768

769



770

771 Figure 5. Serum ADA2 enzymatic activity of suspected DADA2 patients.

772 **A.** ADA2 enzyme activity (U/L) measured in serum samples of suspected DADA2 patients (n=10), adult
 773 healthy controls (n=35), pediatric healthy controls (n=17), healthy DADA2 carriers (n=19) and DADA2
 774 patients (n=18). Each data point is plotted with mean \pm SD. Statistical significance was assessed using

775 the Mann-Whitney U test,*** p<0.0001. **B.** ADA2 protein secretion in Serum samples of pediatric
776 controls, adult controls, DADA2 patients and cohort patients by Western blot. **C-D.** Quantification of
777 ADA2 secretion in Serum samples of pediatric controls, adult controls, DADA2 patients and cohort
778 patients. Bar graphs represent percentage of ADA2 protein secretion relative to Pediatric/adult
779 controls. Each bar represents mean ± SD from 3 independent experiments.

780 Tables

781 Table. 1 Clinical impact of R169Q in the UK Biobank and FinnGen

	Phenotype	UKB (Gen e bass) OR	UKB (Gen e bass) p- valu e	UKB (AZPhewa s) OR	UKB (AZPhewa s) p-value	Finnge n OR	Finnge n p- value
Neurological	Ischemic stroke	1.5	0.4				
	Stroke not specified as hemorrhage or infarction	1.5	0.3				
	Sequelae of cerebrovascular disease	5.8	0.02				
	Headaches	1.4	0.5				
	Vertigo	15.2	0.04				
	Dizziness and giddiness			23.3	0.0013		
	Vascular dementia	2.2	0,5			4.3	0.002
Cutaneous vasculopathy	Livedoid vasculitis					7.4	0.01
	Other and unspecified vasculitis limited to skin	0.4	0,6			5.2	0.01
	Raynaud phenomenon/disea se	3.3	0.4				
Immunologica l/ hematological	Selective deficiency of immunoglobulin A					6.8	0.005
	Immunodeficiency with predominantly antibody defects	0.4	0.6			3.6	0.03
Other cutaneous	Cicatricial alopecia	0.4	0.7			13.1	0.02
	Other and unspecified cicatricial alopecia					8.7	0.01

Bone marrow	Other primary thrombocytopenia					5.5	0.02
	Idiopathic thrombocytopenic purpura			75.40	0.008		
Gastrointestinal	Intestinal malabsorption	1.09	0.9			2.96	0.0003
	Ulcerative colitis	3.39	0.02	26.519	0.0062		
Infections	Infective/viral hepatitis	8.6	0.03				
	Viral warts	0.6	0.04			0.9	0.8
	Cytomegaloviral disease	0.4	0.7			0.3	0.6
Malignancies	Hodgkin lymphoma/ Hodgkin disease	4.4	0.3				
	Myeloid leukemia	18.2	0.03				
Other	Liver/biliary/pancreas problem	14.7	0.003				
	Chronic liver hepatitis	23.8	0.02				
	Joint disorder unspecified			88.47	0.005		
	Hypertrophic cardiomyopathy			110.30	0.0001		

782 OR: Odds ratio.